BI 2536

For research use only. Not for use in humans.

目录号：S1109

Molecular Weight(MW): 521.66

BI 2536是一种有效的Plk1抑制剂，无细胞试验中IC50为0.83 nM，比作用于Plk2和Plk3选择性分别高4和11倍。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1978.87	现货
5mg	RMB 981.57	现货
10mg	RMB 1704.35	现货
50mg	RMB 5492.59	现货
100mg	RMB 8160.83	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的BI 2536发表文献134篇：

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )
Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )
J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )
Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )
J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )
J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

产品安全说明书

PLK抑制剂选择性比较

生物活性

产品描述

BI 2536是一种有效的Plk1抑制剂，无细胞试验中IC50为0.83 nM，比作用于Plk2和Plk3选择性分别高4和11倍。Phase 2。

特性

BI 2536是第一个有效的Plk1选择性抑制剂，抑制 Plk1的标记。

靶点

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

体外研究

除了Plk1, BI 2536也抑制 Plk2 和Plk3活性，只是抑制程度低点,IC50分别为3.5 nM和9.0 nM。BI 2536比一组63种其他蛋白激酶（IC50>10 μM）选择性高1000多倍。BI 2536 按10 nM 到 100 nM剂量作用于HeLa细胞，抑制有丝分裂中心体中γ-微管蛋白招募和Apc6 磷酸化，抑制染色体臂中释放黏结蛋白, 诱导产生单极主轴，及一些依赖Plk1的其他有丝分裂过程。与作用于Plk1 RNAi效果相一致, BI 2536处理HeLa细胞，使细胞周期停在G2/M期, 随后DNA分解及凋亡，且累积断裂的PARP p85片段，这种作用存在浓度依赖性。BI 2536抑制一组32种人肿瘤细胞系生长，EC50为2-25 nM,抑制指数生长的hTERT-RPE1,人脐静脉内皮细胞 (HUVECs),和正常大鼠肾脏(NRK) 细胞的增殖，EC50为12-31 nM。^[1] BI 2536 抑制Plk1，降低甲状腺未分化癌(ATC)细胞如 CAL62, OCUT-1, SW1736, 8505C,和 ACT-1 的生长的生长和活力，EC50为1.4-5.6 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\4TWM2OD1yLkCwO\|c3KM7:TR?=	NVnNbZdjW0GQR1XS
ACN	M2e1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2juWGlEPTB;MD6wNFg1OyEQvF2=	MV;TRW5ITVJ?
TE-8	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PSXWlEPTB;MD6wNFk1OSEQvF2=	M3HtdHNCVkeHUh?=
LC-2-ad	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTUTWM2OD1yLkCxNFk{KM7:TR?=	NVnqd5llW0GQR1XS
ALL-PO	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHlcHB7UUN3ME2wMlAyOyEQvF2=	MnfSV2FPT0WU
EW-16	NFjrd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUWwNJc2UUN3ME2wMlAyOzN4IN88US=>	MonUV2FPT0WU
KM12	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzmTFZKSzVyPUCuNFE{PDhizszN	NFjKU4NUSU6JRWK=
GI-1	NGjxfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwMEGzPFMh\|ryP	MVPTRW5ITVJ?
LS-411N	NY\aWGIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHucoxRUUN3ME2wMlAyPDB5IN88US=>	NXfIfY1KW0GQR1XS
ES8	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTBwMEG0PVQh\|ryP	NXLtcIhLW0GQR1XS
SNU-C2B	M1myUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mle2TWM2OD1yLkCxOVI3KM7:TR?=	MoruV2FPT0WU
CESS	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILjT3JKSzVyPUCuNFE3ODJizszN	M3LLeHNCVkeHUh?=
697	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nUTWlEPTB;MD6wNVY3QCEQvF2=	Mki2V2FPT0WU
NCI-H1963	NYe4dGFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fSRWlEPTB;MD6wNVY4OyEQvF2=	MV7TRW5ITVJ?
IA-LM	NXTOPJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfOOVNKSzVyPUCuNFE3QDhizszN	M2e1U3NCVkeHUh?=
SW954	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTBwMEG3NFUh\|ryP	NXTjeZlxW0GQR1XS
RL95-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUexUG55UUN3ME2wMlAyPzN6IN88US=>	MkLiV2FPT0WU
LXF-289	M4XVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTBwMEG3O{DPxE1?	NYXBfmxqW0GQR1XS
OCUB-M	NXzsSnNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnqyTWM2OD1yLkCxPFI3KM7:TR?=	NHHTRYtUSU6JRWK=
RKO	NWPibmp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPwVZZKSzVyPUCuNFE6QDdizszN	MUHTRW5ITVJ?
LOUCY	MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV22fGJNUUN3ME2wMlAzODVizszN	NWrBdY1WW0GQR1XS
NOS-1	MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTBwMEKwPVMh\|ryP	MXHTRW5ITVJ?
A4-Fuk	NVfISVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrZNZNKSzVyPUCuNFIzOThizszN	NELwO4pUSU6JRWK=
A388	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PnbWlEPTB;MD6wNlIzPyEQvF2=	M{H3NnNCVkeHUh?=
TE-9	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHycHdvUUN3ME2wMlAzOjZzIN88US=>	M2\nbnNCVkeHUh?=
KURAMOCHI	NYDIWnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPXUJk4UUN3ME2wMlAzOjh3IN88US=>	MoXjV2FPT0WU
KALS-1	NXTO[m1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGf2bIhKSzVyPUCuNFI{OzhizszN	NYLLXpI6W0GQR1XS
HOP-62	NGXCeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjqTWM2OD1yLkCyOFIh\|ryP	NV\2Z4J{W0GQR1XS
RPMI-8402	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\yO2lEPTB;MD6wNlUxQCEQvF2=	NIjhcFVUSU6JRWK=
TE-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7wTWM2OD1yLkCyOVEzKM7:TR?=	MWTTRW5ITVJ?
CCRF-CEM	M1PFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlq4TWM2OD1yLkCyOVQ{KM7:TR?=	MlLtV2FPT0WU
HUTU-80	NEi2cJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTLUGM{UUN3ME2wMlAzPjJ2IN88US=>	M332bHNCVkeHUh?=
NCI-H1648	NIXCUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPTTWM2OD1yLkCyOlQ4KM7:TR?=	NUnMXlJuW0GQR1XS
HCE-4	NEnkWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrRTWM2OD1yLkCyOlgzKM7:TR?=	NWLtd2ZqW0GQR1XS
ETK-1	Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\y[GlEPTB;MD6wNlc{PiEQvF2=	M1HRe3NCVkeHUh?=
TE-15	NWHvb\|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTBwMEK3N\|gh\|ryP	Mlz1V2FPT0WU
BE-13	M3foU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTBwMEK3OEDPxE1?	M3PNd3NCVkeHUh?=
KE-37	NFjZZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LpU2lEPTB;MD6wNlc1OSEQvF2=	MnTZV2FPT0WU
NCI-H1355	NXvLUmZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTBwMEK3PFMh\|ryP	NHPRUo1USU6JRWK=
TE-11	Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSwN5NbUUN3ME2wMlAzQDB7IN88US=>	M4P5O3NCVkeHUh?=
BL-70	NFvFXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH70OmVKSzVyPUCuNFI5PTdizszN	MmTJV2FPT0WU
ES6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXKZ3VKSzVyPUCuNFI5QDFizszN	NUHxU3Y1W0GQR1XS
GT3TKB	M{i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTBwMEK5OVMh\|ryP	NHuxeHlUSU6JRWK=
LB647-SCLC	NGXPU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrMXIJYUUN3ME2wMlA{OTl3IN88US=>	M3mwenNCVkeHUh?=
NB13	M1KyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\5TWM2OD1yLkCzN\|E3KM7:TR?=	NIG0OFFUSU6JRWK=
ST486	NEjxcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Pwd2lEPTB;MD6wN\|M{PyEQvF2=	MmP3V2FPT0WU
NCI-H82	M3niNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMEOzOFMh\|ryP	NH3mPGNUSU6JRWK=
NTERA-S-cl-D1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTBwMEOzPVkh\|ryP	NWXwVZljW0GQR1XS
ES4	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\WTWM2OD1yLkCzOFY{KM7:TR?=	NHK2bXRUSU6JRWK=
SK-NEP-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWT2PY1QUUN3ME2wMlA{PDl7IN88US=>	NW\Tc2hRW0GQR1XS
Becker	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwMEO1OVUh\|ryP	NHHhVGxUSU6JRWK=
A101D	NIXJdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXHTWM2OD1yLkCzO\|Q5KM7:TR?=	MVTTRW5ITVJ?
SK-UT-1	NVXEfYJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTBwMEO3O\|Qh\|ryP	MXnTRW5ITVJ?
SW982	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTBwMEO3PUDPxE1?	NVHYRnd5W0GQR1XS
TE-10	NFKyTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTBwMESwOFYh\|ryP	NXPxOZlVW0GQR1XS
OVCAR-4	M2P3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvvN2xKSzVyPUCuNFQxPTlizszN	MV;TRW5ITVJ?
KP-N-YS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj6SpJKSzVyPUCuNFQxQDVizszN	NFPQT4VUSU6JRWK=
BL-41	NEXielhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUO3S3VGUUN3ME2wMlA1OTJ3IN88US=>	NYfqb5Y6W0GQR1XS
MZ1-PC	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMESxNlch\|ryP	MnzhV2FPT0WU
PF-382	M4PqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnLTWM2OD1yLkC0NVk5KM7:TR?=	M3T1OHNCVkeHUh?=
MOLT-13	M165VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjHOVNKSzVyPUCuNFQzOzhizszN	M1LaVHNCVkeHUh?=
HCC1599	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7ESolPUUN3ME2wMlA1OjV6IN88US=>	M3j2b3NCVkeHUh?=
IST-MEL1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfDZnhKSzVyPUCuNFQ1PDJizszN	MXLTRW5ITVJ?
LU-139	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTBwMES0OFIh\|ryP	M2TjXnNCVkeHUh?=
MS-1	M13Gemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXwbXBKSzVyPUCuNFQ4ODFizszN	MlLJV2FPT0WU
MFH-ino	M3exN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PXUmlEPTB;MD6wOVAxOyEQvF2=	NVXPVlVPW0GQR1XS
IMR-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\4dGlEPTB;MD6wOVAzOSEQvF2=	NVOyS5NjW0GQR1XS
TE-5	NYrZXGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrlVGtKSzVyPUCuNFUxPjNizszN	MYLTRW5ITVJ?
DJM-1	NGjWclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHjNGxEUUN3ME2wMlA2OTR{IN88US=>	M{jiZXNCVkeHUh?=
NB17	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLHdlBKSzVyPUCuNFUzODdizszN	MlTwV2FPT0WU
KARPAS-45	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\P[mlEPTB;MD6wOVM2QCEQvF2=	M4PDZ3NCVkeHUh?=
TGBC1TKB	NHPU[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PjcWlEPTB;MD6wOVQxPSEQvF2=	MmDiV2FPT0WU
ML-2	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHYN4hRUUN3ME2wMlA2PDF2IN88US=>	MlPYV2FPT0WU
no-10	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTNVVQxUUN3ME2wMlA2PDd2IN88US=>	MXzTRW5ITVJ?
CTV-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrKd2x4UUN3ME2wMlA2PTB{IN88US=>	MoPjV2FPT0WU
SJSA-1	MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTBwMEW1NkDPxE1?	NI\TWmFUSU6JRWK=
HC-1	NFzUfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwMEW1PVch\|ryP	MWXTRW5ITVJ?
TE-12	NHL3bpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jy[mlEPTB;MD6wOVYyOyEQvF2=	M4rvTHNCVkeHUh?=
KY821	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PtWGlEPTB;MD6wOVY{OiEQvF2=	NIDSfG1USU6JRWK=
TALL-1	M1\jWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjhcXlKSzVyPUCuNFU4ODhizszN	NUflN\|d3W0GQR1XS
DEL	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTBwMEW3NFkh\|ryP	Mk\MV2FPT0WU
TE-6	NETDVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmq0TWM2OD1yLkC1O\|IzKM7:TR?=	NVrlb5RDW0GQR1XS
SK-LMS-1	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzRTWM2OD1yLkC1PFA2KM7:TR?=	M3\3cHNCVkeHUh?=
EW-1	M3\3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHHfpFyUUN3ME2wMlA2QDN5IN88US=>	MULTRW5ITVJ?
8-MG-BA	MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWG1XoFMUUN3ME2wMlA2QDVzIN88US=>	MkXkV2FPT0WU
NALM-6	NX\yW4FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwMEW5O\|Mh\|ryP	MkTjV2FPT0WU
LB771-HNC	NFz2fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\YZ2lEPTB;MD6wOVk4QSEQvF2=	NEXSc2dUSU6JRWK=
HT-144	NGCxW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;6bWlEPTB;MD6wOlE{KM7:TR?=	M1Lm[nNCVkeHUh?=
KM-H2	NGjKUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\oXWlEPTB;MD6wOlIzOSEQvF2=	NX;6NYhbW0GQR1XS
SF268	NIjXNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHoTWM2OD1yLkC2Nlg3KM7:TR?=	NEnDemlUSU6JRWK=
RS4-11	M{nDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzPeo9KSzVyPUCuNFY{ODRizszN	NVXhc\|V6W0GQR1XS
MHH-PREB-1	Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmW4TWM2OD1yLkC2N\|E6KM7:TR?=	NVvIOmp2W0GQR1XS
ATN-1	NInuUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3acnlGUUN3ME2wMlA3OzR3IN88US=>	MnTJV2FPT0WU
BB30-HNC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwME[0N\|Yh\|ryP	NFHieHRUSU6JRWK=
CPC-N	M4Sye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HNVWlEPTB;MD6wOlUzPCEQvF2=	MVTTRW5ITVJ?
NB1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPYV3ZjUUN3ME2wMlA3PjF\|IN88US=>	MX;TRW5ITVJ?
KS-1	M3LqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnuRnlKSzVyPUCuNFY4PDhizszN	M1vxSXNCVkeHUh?=
RXF393	NG\tV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO2eWZ6UUN3ME2wMlA3PzZ2IN88US=>	NFTCfmFUSU6JRWK=
IST-SL2	NVnDWZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zMdWlEPTB;MD6wO\|AxPCEQvF2=	MoTkV2FPT0WU
GI-ME-N	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHzXo5UUUN3ME2wMlA4Ojh4IN88US=>	NUHqXWR1W0GQR1XS
VA-ES-BJ	NHTyc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfBTWM2OD1yLkC3OFc2KM7:TR?=	NYTOTJRHW0GQR1XS
NCI-H1581	NWT0PYFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnTTWM2OD1yLkC3OFc5KM7:TR?=	M2Xw[HNCVkeHUh?=
U-266	MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIW1VmhKSzVyPUCuNFc1QTdizszN	M3S0[XNCVkeHUh?=
DMS-114	NGrSc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rHWmlEPTB;MD6wO\|UzQCEQvF2=	NWrtco92W0GQR1XS
NCI-H187	NYDkRXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVO4Xo1yUUN3ME2wMlA4PzJ4IN88US=>	NEP5eo1USU6JRWK=
SW962	NYnjRnR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vzR2lEPTB;MD6wO\|g{QSEQvF2=	MUPTRW5ITVJ?
MONO-MAC-6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTL[ZpUUUN3ME2wMlA4QTh4IN88US=>	M2nwNnNCVkeHUh?=
MOLT-16	NHzKfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTBwMEixNlEh\|ryP	M1XJeHNCVkeHUh?=
KNS-42	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnDW3VKSzVyPUCuNFgyPjFizszN	MXXTRW5ITVJ?
CMK	M{ftUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoK4TWM2OD1yLkC4NlI2KM7:TR?=	M37lUHNCVkeHUh?=
Ramos-2G6-4C10	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\rVWdKSzVyPUCuNFgzOjVizszN	M3PqdnNCVkeHUh?=
Daudi	M3HvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nVUWlEPTB;MD6wPFI2PiEQvF2=	MlraV2FPT0WU
NCI-H510A	M3;i[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33DRmlEPTB;MD6wPFM{PiEQvF2=	MU\TRW5ITVJ?
LB831-BLC	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LiVWlEPTB;MD6wPFU3OSEQvF2=	NH;hNW5USU6JRWK=
HEL	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\NSXRKSzVyPUCuNFg3PjhizszN	MVLTRW5ITVJ?
LU-134-A	M{PRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrFPJZxUUN3ME2wMlA5PzB6IN88US=>	Mo\ZV2FPT0WU
NCI-H1694	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrETJpKSzVyPUCuNFg4PDRizszN	MnTIV2FPT0WU
KGN	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjrTWM2OD1yLkC4O\|U6KM7:TR?=	NXzaOIREW0GQR1XS
A253	NWn2ZZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vLUGlEPTB;MD6wPFgzOiEQvF2=	MU\TRW5ITVJ?
DG-75	M{H5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrlN3VKSzVyPUCuNFg6OjJizszN	MVfTRW5ITVJ?
MOLT-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTBwMEi5PFMh\|ryP	NFXOVIhUSU6JRWK=
NCI-SNU-5	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMEmyOVgh\|ryP	NHrmdXFUSU6JRWK=
ONS-76	NHLBZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7CdlJrUUN3ME2wMlA6Ojd4IN88US=>	NX64e3hsW0GQR1XS
NCI-H446	M{K3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[2UWVzUUN3ME2wMlA6PDZ{IN88US=>	Mn\TV2FPT0WU
COR-L279	M3;CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnzfVlKSzVyPUCuNFk2PTZizszN	NH35XoZUSU6JRWK=
Calu-6	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYniXYYzUUN3ME2wMlA6PTl6IN88US=>	NV[wdYVRW0GQR1XS
BC-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{D5WWlEPTB;MD6wPVY3OiEQvF2=	MknzV2FPT0WU
NCI-H2126	NFziNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XQ[GlEPTB;MD6wPVc6OSEQvF2=	MULTRW5ITVJ?
NCI-H1882	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjTTWM2OD1yLkC5PFA6KM7:TR?=	NFTXWZVUSU6JRWK=
BB65-RCC	NYDRSIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXWz[FlnUUN3ME2wMlExOjl2IN88US=>	M2PkTnNCVkeHUh?=
DU-4475	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTBwMUC0NFch\|ryP	NVLrbZJ4W0GQR1XS
NCI-H526	M4rVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3vUZJCUUN3ME2wMlExPDRizszN	NGi4clZUSU6JRWK=
NEC8	NVTubW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jTZmlEPTB;MD6xNFUzPSEQvF2=	MofLV2FPT0WU
NCI-H1304	NGfVTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjjfpJKSzVyPUCuNVA2QTRizszN	M4rFc3NCVkeHUh?=
L-540	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwMUC3NFgh\|ryP	NUjse2JMW0GQR1XS
NCI-SNU-16	NYDCWml[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrhcXFKSzVyPUCuNVA4PDJizszN	MX\TRW5ITVJ?
HD-MY-Z	NYKyVJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX76[Y5FUUN3ME2wMlExQDV4IN88US=>	NFjWV3NUSU6JRWK=
K-562	M2rJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTBwMUC4OVgh\|ryP	NW\lXWp3W0GQR1XS
JAR	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTBwMUC5NlUh\|ryP	MUfTRW5ITVJ?
MZ2-MEL	NWmxO5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\yTWM2OD1yLkGxNFUh\|ryP	MkO5V2FPT0WU
L-363	NGXCTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;BTlA6UUN3ME2wMlEyODd7IN88US=>	NXf6d5VnW0GQR1XS
BV-173	M1n5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml74TWM2OD1yLkGxNlQ{KM7:TR?=	MUXTRW5ITVJ?
NCI-H524	NFr5eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED3Z5hKSzVyPUCuNVEzPzRizszN	M4nIRXNCVkeHUh?=
EoL-1-cell	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LDV2lEPTB;MD6xNVY4OiEQvF2=	NFvUdlJUSU6JRWK=
K052	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnm1TWM2OD1yLkGxO\|EzKM7:TR?=	M1\UOnNCVkeHUh?=
TK10	NFz4OmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\i[mlEPTB;MD6xNVczQCEQvF2=	NVzVc4s1W0GQR1XS
KU812	NXTNXoF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HDSmlEPTB;MD6xNlA1PCEQvF2=	M4r2U3NCVkeHUh?=
RPMI-8226	NXTOSppqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFK4bGlKSzVyPUCuNVIxPTJizszN	M2HLUnNCVkeHUh?=
MZ7-mel	M4nXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjqfYtKSzVyPUCuNVIzOzdizszN	MVrTRW5ITVJ?
SK-PN-DW	NYTtVldmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFH0TFBKSzVyPUCuNVIzQDdizszN	NYPxeZc6W0GQR1XS
SR	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorGTWM2OD1yLkGyOFQyKM7:TR?=	M4nUOHNCVkeHUh?=
RPMI-6666	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwMUK3OFMh\|ryP	NIjzO5BUSU6JRWK=
no-11	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTBwMUK4Olkh\|ryP	NF2zeI1USU6JRWK=
EW-3	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDWTWM2OD1yLkGyPFk{KM7:TR?=	NFWz[3FUSU6JRWK=
LAMA-84	NVj4WZYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DodmlEPTB;MD6xN\|E5PyEQvF2=	NVXlPJU5W0GQR1XS
HT	NUnGN4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;PcXZKSzVyPUCuNVM2PzRizszN	MYHTRW5ITVJ?
KP-N-RT-BM-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTBwMUO2NVIh\|ryP	MonGV2FPT0WU
NCI-H747	MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTBwMUO3JO69VQ>?	MnLpV2FPT0WU
NCCIT	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4C2VWlEPTB;MD6xN\|k{QSEQvF2=	MX;TRW5ITVJ?
MLMA	NGrIdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTBwMUSxOlch\|ryP	NYL3UGlNW0GQR1XS
LP-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXudVFKSzVyPUCuNVQzPCEQvF2=	NWTzdVFXW0GQR1XS
CAL-148	NIrjUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfHTWM2OD1yLkG0OFg{KM7:TR?=	NXvvWGpIW0GQR1XS
GB-1	NUDJVop5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnUTWM2OD1yLkG0OVI3KM7:TR?=	NFHU[YtUSU6JRWK=
COR-L88	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfXTWM2OD1yLkG0PFAzKM7:TR?=	Mli0V2FPT0WU
NKM-1	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1e5cGlEPTB;MD6xOFkxPiEQvF2=	MkXMV2FPT0WU
NB5	NH72fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWf1U2pyUUN3ME2wMlE2PDZ{IN88US=>	MY\TRW5ITVJ?
SH-4	NGnYUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\6XmFKSzVyPUCuNVU1PjZizszN	NFrCPJpUSU6JRWK=
EM-2	NHj0SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvVTWM2OD1yLkG1OFY4KM7:TR?=	M3y2VnNCVkeHUh?=
TGBC24TKB	NY[4THdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnYOpFKSzVyPUCuNVU3PTlizszN	M1viTnNCVkeHUh?=
SCLC-21H	NVjDVm5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LV[2lEPTB;MD6xOVcxOiEQvF2=	MX\TRW5ITVJ?
COLO-684	NIHNfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfxdVBKSzVyPUCuNVU4OjFizszN	MV;TRW5ITVJ?
KINGS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHXb5huUUN3ME2wMlE2QTFizszN	MVzTRW5ITVJ?
LS-123	M373dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITwOJVKSzVyPUCuNVU6OTdizszN	NUO3TmRMW0GQR1XS
MC116	NF7qZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\GbGlEPTB;MD6xOlE2QCEQvF2=	MkDWV2FPT0WU
SU-DHL-1	NF;XUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoSzTWM2OD1yLkG2NlA3KM7:TR?=	M1PLTXNCVkeHUh?=
NCI-H64	M4W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwMU[zOFch\|ryP	MWLTRW5ITVJ?
HCE-T	M2PUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DLc2lEPTB;MD6xOlUxPCEQvF2=	MV;TRW5ITVJ?
LOXIMVI	NF\GNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfFOoFKSzVyPUCuNVY6PDlizszN	M2Wxb3NCVkeHUh?=
ARH-77	M33CSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHhdXJKSzVyPUCuNVc{PzlizszN	MYXTRW5ITVJ?
DOHH-2	NH7I[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XuV2lEPTB;MD6xO\|Y4OiEQvF2=	NV30e3NRW0GQR1XS
COLO-320-HSR	NX3hWI1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXxTWM2OD1yLkG4NVU1KM7:TR?=	NHf5O4lUSU6JRWK=
NB6	M1jT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;je45KSzVyPUCuNVg2PjZizszN	M1vHVXNCVkeHUh?=
L-428	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH2xbYhKSzVyPUCuNVg5OTNizszN	M2i3dXNCVkeHUh?=
SNB75	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7KN4NKSzVyPUCuNVg5OjRizszN	NVPoZ4JxW0GQR1XS
NCI-H2141	M3;mdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwMUmwNVEh\|ryP	MmnHV2FPT0WU
KARPAS-299	NH7V[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1qx[mlEPTB;MD6xPVI1OSEQvF2=	MlfLV2FPT0WU
LC4-1	NFrWeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTBwMUm1NFIh\|ryP	MkmyV2FPT0WU
UACC-257	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF:2XZZKSzVyPUCuNVk6PDdizszN	M2HG[HNCVkeHUh?=
EVSA-T	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXiTWM2OD1yLkKwN\|EzKM7:TR?=	NELwUW9USU6JRWK=
JiyoyeP-2003	M1u2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHmXXFMUUN3ME2wMlIxPDd5IN88US=>	MUfTRW5ITVJ?
NCI-H720	M1ewOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\JcFFKSzVyPUCuNlA2OjVizszN	NFy1Z4pUSU6JRWK=
GAK	NFnKN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMkGxPFkh\|ryP	NVnoOpFCW0GQR1XS
HH	NF;zT\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLkVodCUUN3ME2wMlIyPDB3IN88US=>	MVPTRW5ITVJ?
NCI-H1436	NWHlR5BuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUWyd2w3UUN3ME2wMlIyPDZ2IN88US=>	MUDTRW5ITVJ?
GR-ST	NYXNU2tXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrHS\|NYUUN3ME2wMlIyPDh6IN88US=>	MVjTRW5ITVJ?
BC-1	NWSyfmNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTSWINKSzVyPUCuNlI3OTZizszN	M12yUHNCVkeHUh?=
SIG-M5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr6bodKSzVyPUCuNlI4OjdizszN	NEThfllUSU6JRWK=
NCI-H345	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLId3NKSzVyPUCuNlM5ODVizszN	Ml24V2FPT0WU
OPM-2	M{GxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\rU\|hKSzVyPUCuNlM5QDJizszN	MUnTRW5ITVJ?
LB1047-RCC	NXnne\|VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTBwMkS0NUDPxE1?	MlLMV2FPT0WU
CTB-1	M{f1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPTTWM2OD1yLkK0OFk{KM7:TR?=	MYjTRW5ITVJ?
A3-KAW	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHz2VZBKSzVyPUCuNlU{PDFizszN	MVfTRW5ITVJ?
SF126	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rtVGlEPTB;MD6yOVM5OyEQvF2=	Mkm1V2FPT0WU
KARPAS-422	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{X1ZWlEPTB;MD6yOVQ{PSEQvF2=	NHzCXJBUSU6JRWK=
MEG-01	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLQXoZKSzVyPUCuNlU3PzNizszN	NV;4O49KW0GQR1XS
NCI-H209	MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoT3TWM2OD1yLkK2N\|c1KM7:TR?=	NX3icJZtW0GQR1XS
SBC-1	NWDld4x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HOU2lEPTB;MD6yOlUh\|ryP	MU\TRW5ITVJ?
K5	M4XENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTBwMk[5PFQh\|ryP	M{nvTnNCVkeHUh?=
QIMR-WIL	NEHpcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nLXmlEPTB;MD6yO\|E2PSEQvF2=	NGizO\|VUSU6JRWK=
NMC-G1	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwMkiyNVch\|ryP	MWHTRW5ITVJ?
IST-MES1	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzSTWM2OD1yLkK5NlM5KM7:TR?=	Ml7aV2FPT0WU
SW684	M3;0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrRU5FKSzVyPUCuN\|AxPDdizszN	MXjTRW5ITVJ?
MV-4-11	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmCzTWM2OD1yLkOwO\|g5KM7:TR?=	NIjXVXJUSU6JRWK=
LAN-6	NXjHSGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUL4NHllUUN3ME2wMlMyPTd{IN88US=>	NYLGUppEW0GQR1XS
RH-1	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwM{G4O\|Eh\|ryP	Mnf4V2FPT0WU
CP66-MEL	NELNbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jtVGlEPTB;MD6zNVg4QCEQvF2=	MWDTRW5ITVJ?
EC-GI-10	NGjrSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwM{K5PFch\|ryP	NEC3b3JUSU6JRWK=
GDM-1	NE\5bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:wcY9KSzVyPUCuN\|MxPTlizszN	MnfiV2FPT0WU
IST-SL1	NHrEW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3FfpRKSzVyPUCuN\|Q6OTRizszN	MlvnV2FPT0WU
KMOE-2	Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n2dGlEPTB;MD6zOVE4PSEQvF2=	NIfPN4hUSU6JRWK=
OS-RC-2	Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwM{W1OFQh\|ryP	NF71UGZUSU6JRWK=
HDLM-2	NGOyWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPNcm1KSzVyPUCuN\|c5OTRizszN	NU\USVZtW0GQR1XS
DSH1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTBwM{i2N\|Eh\|ryP	NGXOcHdUSU6JRWK=
LS-1034	NXnINIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLwTWM2OD1yLkO4PVU1KM7:TR?=	MYDTRW5ITVJ?
LB373-MEL-D	NEW4XodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTBwM{mxPVch\|ryP	NETPRmJUSU6JRWK=
GOTO	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;mZ2lEPTB;MD60NlEyQCEQvF2=	NYnPdnc4W0GQR1XS
MRK-nu-1	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTBS2FGUUN3ME2wMlQzOjB3IN88US=>	NHG5V\|RUSU6JRWK=
SK-MM-2	M1ywWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzjTWM2OD1yLkSzOFQzKM7:TR?=	MUTTRW5ITVJ?
BOKU	NHTqXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXDU3pKSzVyPUCuOFM4QTJizszN	NYj6fWZuW0GQR1XS
NOMO-1	NF3uZ\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfr[okyUUN3ME2wMlQ{QDZizszN	M{OyTXNCVkeHUh?=
J-RT3-T3-5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwNES4O\|gh\|ryP	M2qxSnNCVkeHUh?=
COLO-668	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTBwNEW2Olgh\|ryP	MonKV2FPT0WU
SF539	MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzhPWpKSzVyPUCuOFg3QDRizszN	NHnvXVJUSU6JRWK=
LB2518-MEL	NGDOWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXlbYxKSzVyPUCuOFk4ODNizszN	MUfTRW5ITVJ?
TE-441-T	MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\sTINrUUN3ME2wMlUxOTJizszN	MX3TRW5ITVJ?
MDA-MB-134-VI	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjpXmRVUUN3ME2wMlUxQTJzIN88US=>	NWrDO4h4W0GQR1XS
SCC-3	M2DXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTBVHlMUUN3ME2wMlUyQDd\|IN88US=>	MnjOV2FPT0WU
KLE	NEfocWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTBwNUKxO\|Eh\|ryP	MnjTV2FPT0WU
LB2241-RCC	M1f0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjDcGNKSzVyPUCuOVI2OjVizszN	MlnEV2FPT0WU
NCI-H1417	NETnZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LDbmlEPTB;MD61N\|Q{PSEQvF2=	MmO4V2FPT0WU
NCI-H2081	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfPPFdKSzVyPUCuOVg3OTFizszN	MkXyV2FPT0WU
NCI-H1522	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrLc4xKSzVyPUCuOVk{QDNizszN	M4DVbnNCVkeHUh?=
NCI-H889	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFGx[HBKSzVyPUCuOVk5PDRizszN	Ml\wV2FPT0WU
CGTH-W-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\kfWlEPTB;MD62NFc2PSEQvF2=	MVXTRW5ITVJ?
EB-3	Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvkT29mUUN3ME2wMlYyOTV\|IN88US=>	M17WbXNCVkeHUh?=
D-336MG	NVPN[oliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nufGlEPTB;MD62NVc6OSEQvF2=	M3z1WXNCVkeHUh?=
LC-1F	NETwNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYGxUII1UUN3ME2wMlYzPTl{IN88US=>	MoTSV2FPT0WU
MHH-NB-11	M17tVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwNkO4NFEh\|ryP	NF3vUI9USU6JRWK=
SK-N-FI	NULIZphST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u0eWlEPTB;MD62N\|kyKM7:TR?=	MV3TRW5ITVJ?
NCI-H69	M{nlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;ETWM2OD1yLk[0PFc6KM7:TR?=	Ml6zV2FPT0WU
SCH	M1rCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwNk[wNlMh\|ryP	NFXiSnNUSU6JRWK=
LS-513	NVmweHdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTBwNkeyOVkh\|ryP	M2fvTHNCVkeHUh?=
CP67-MEL	NX7jXJBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTBwNke1PVYh\|ryP	NULUeXZYW0GQR1XS
GCIY	NEnuPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmSxTWM2OD1yLkewN\|Y{KM7:TR?=	MYLTRW5ITVJ?
SHP-77	NX3iVJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwN{C3N\|Qh\|ryP	MlG3V2FPT0WU
EHEB	M3PzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTBwN{G4OVQh\|ryP	MkflV2FPT0WU
D-247MG	NXnkTVljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnW3TWM2OD1yLkezNlMzKM7:TR?=	NIG3UZVUSU6JRWK=
Raji	NUDn[VFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrINJpKSzVyPUCuO\|Q6QDlizszN	MYXTRW5ITVJ?
MPP-89	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHCTotPUUN3ME2wMlc2QTd6IN88US=>	MVXTRW5ITVJ?
EKVX	NW\TXJhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTBwN{mwO\|Mh\|ryP	MV\TRW5ITVJ?
HCC2218	NFjWUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3GwdWlEPTB;MD63PVE{OSEQvF2=	NXf2ZXVZW0GQR1XS
KNS-81-FD	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwOEGwNVEh\|ryP	MWrTRW5ITVJ?
HCC2157	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkWxTWM2OD1yLki0PVUyKM7:TR?=	MVvTRW5ITVJ?
BT-474	NFfVd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3mVmNKSzVyPUCuPFg5PTRizszN	M3P3[3NCVkeHUh?=
NCI-H748	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvEblA1UUN3ME2wMlkyOiEQvF2=	NVToNmx3W0GQR1XS
EW-24	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPhRoN[UUN3ME2wMlkzODB{IN88US=>	NGnzXYVUSU6JRWK=
D-263MG	M1fkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLKcndKSzVyPUCuPVQ2OTJizszN	MonzV2FPT0WU
OMC-1	NUn6d45ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPhUnFKSzVyPUCuPVY{PzNizszN	M3PLS3NCVkeHUh?=
NCI-H2196	M2CzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTBwOUe3O\|ch\|ryP	MkLCV2FPT0WU
HAL-01	M3z3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjXTWM2OD1yLkm5PFczKM7:TR?=	M3zqNnNCVkeHUh?=
NCI-H2107	NW\JXVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HIOWlEPTB;MT6wNVg2PCEQvF2=	M1jD[XNCVkeHUh?=
LB996-RCC	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFwMEiwOVEh\|ryP	NH;OdVdUSU6JRWK=
NCI-H1395	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLZSXFzUUN3ME2xMlExPjdizszN	MoXkV2FPT0WU
CHP-126	NFHHeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moe5TWM2OD1zLkG2NVk6KM7:TR?=	MX\TRW5ITVJ?
NB69	M{HrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX[1SpdJUUN3ME2xMlI3OTR6IN88US=>	MnzUV2FPT0WU
CAS-1	NHHzR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3QTWM2OD1zLkO0NlMyKM7:TR?=	MoPxV2FPT0WU
JVM-3	NIPR[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFwNEe4OVUh\|ryP	MYjTRW5ITVJ?
DMS-153	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVH6b5ByUUN3ME2xMlU4Pjd2IN88US=>	MYHTRW5ITVJ?
SK-MEL-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWT0ZYx2UUN3ME2xMlcyPzh7IN88US=>	NI\HUplUSU6JRWK=
NCI-H1155	NEL0bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFwN{O2O\|Yh\|ryP	NGLMR4RUSU6JRWK=
NCI-H1092	M2TsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTFwN{[xPFIh\|ryP	M1naSXNCVkeHUh?=
LU-165	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEGwXIJKSzVyPUGuPFY1PzZizszN	M4fXTnNCVkeHUh?=
HL-60	NWe5cpZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnZfYJKSzVyPUGuPVk6ODhizszN	M4S2THNCVkeHUh?=
REH	NUTiW3hPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJwMEC1PFIh\|ryP	Mn73V2FPT0WU
JVM-2	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDBTWM2OD1{LkC2NVM2KM7:TR?=	NF7xXFdUSU6JRWK=
MN-60	MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJwMUezNFgh\|ryP	NG[w[4lUSU6JRWK=
SCC-15	NX;FVmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTpTWM2OD1{LkKwNlch\|ryP	M1rUOXNCVkeHUh?=
SNU-C1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nCdmlEPTB;Mj6yNVM1OyEQvF2=	MnHkV2FPT0WU
SK-MEL-1	NFv0bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVv4UJFMUUN3ME2yMlMzODR5IN88US=>	M1PzO3NCVkeHUh?=
TGW	NH36UotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJwM{WwNlch\|ryP	NGTEW2NUSU6JRWK=
CA46	M{D3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DpdGlEPTB;Mj63OVk3PyEQvF2=	MXPTRW5ITVJ?
NCI-H23	NEj4Z\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULtWZRrUUN3ME2yMlgxPzlzIN88US=>	NV3V[phjW0GQR1XS
MMAC-SF	NF3oXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmr4TWM2OD1{Lki2OlI5KM7:TR?=	NYmyT2FsW0GQR1XS
NCI-H2171	NX\aWG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfQT5JKSzVyPUOuNFM1PDhizszN	MmjpV2FPT0WU
A704	NUD3NVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nyUmlEPTB;Mz6xOFE6PCEQvF2=	NYj3PIhnW0GQR1XS
DB	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jQZ2lEPTB;Mz6yOVU4PiEQvF2=	MofQV2FPT0WU
NCI-H719	M{HyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{[5T2lEPTB;Mz6zNFM5PCEQvF2=	NWqweZZUW0GQR1XS
MC-CAR	MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF:4XWpKSzVyPUOuOVQ5OTdizszN	Mn[4V2FPT0WU
SIMA	NF\OTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPUdJNFUUN3ME2zMlU5PDF4IN88US=>	NVjOV2JsW0GQR1XS
SW872	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HNVmlEPTB;Mz63PFExOSEQvF2=	NIO0[25USU6JRWK=
HCC1187	NWHSc5lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTNwN{izNVUh\|ryP	MlnFV2FPT0WU
EW-13	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnEUlJwUUN3ME2zMlg{PDF5IN88US=>	NG\yTIFUSU6JRWK=
NCI-SNU-1	NV3kcZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfoTWM2OD12LkKxPVk6KM7:TR?=	M3r4VnNCVkeHUh?=
NCI-H226	NIXlVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGWzRolKSzVyPUSuN\|M3ODZizszN	NEfoV5JUSU6JRWK=
RPMI-8866	M361fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DpWmlEPTB;ND6zOlAzQSEQvF2=	NUTkdFRMW0GQR1XS
OCI-AML2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1L5WGlEPTB;ND61OVI{KM7:TR?=	NV:3ZYp4W0GQR1XS
LU-65	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHGTWM2OD12LkmzNFM{KM7:TR?=	NIryS2VUSU6JRWK=
SK-N-DZ	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTVwNkO0OlUh\|ryP	NXi4SmgyW0GQR1XS
NB14	NV;6Z3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTVwOUexN\|Uh\|ryP	MoKwV2FPT0WU
COLO-829	M4T4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDp[4R7UUN3ME22MlM{OzV7IN88US=>	NUHN[5M6W0GQR1XS
MHH-CALL-2	M1HIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;CPW1KSzVyPU[uOVE2ODhizszN	MV7TRW5ITVJ?
NCI-H1770	M{XpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjqTWM2OD14Lk[2PVA1KM7:TR?=	NV7Wb2JnW0GQR1XS
ECC4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTCWoZKSzVyPU[uPFIyPzlizszN	NVvOO\|FXW0GQR1XS
A498	NFvWVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTZwOEexPVIh\|ryP	Mn3vV2FPT0WU
DMS-79	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M171S2lEPTB;Nz6wOFUyOiEQvF2=	NFW0VZRUSU6JRWK=
P30-OHK	NX3xd5htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITwV\|dKSzVyPUeuNlE6ODZizszN	NYHKZ20{W0GQR1XS
D-502MG	NXnUWY9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTdwOUizOkDPxE1?	NFXteI5USU6JRWK=
RCC10RGB	NUPURm1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRThwME[yPEDPxE1?	MXfTRW5ITVJ?
U-698-M	NUm4UFhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPIcGxKSzVyPUiuNlkzOjZizszN	NFXLfVZUSU6JRWK=
BB49-HNC	NX7QN3FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXKzflFlUUN3ME25MlQzOjZ3IN88US=>	M3HXXHNCVkeHUh?=
ES1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLKTWM2OD17Lk[4PVU3KM7:TR?=	NIS3bplUSU6JRWK=
MFM-223	M3fRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELHSFBKSzVyPUGwMlk6OjdizszN	M3u4WHNCVkeHUh?=
C2BBe1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTjc2dPUUN3ME2xNU4{PTJ\|IN88US=>	MkXQV2FPT0WU
EB2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XwO2lEPTB;MUKuOlg5OSEQvF2=	MmW4V2FPT0WU
C8166	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnxTWM2OD1zMz64N\|A{KM7:TR?=	M2G4[nNCVkeHUh?=
ES3	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrOO49KSzVyPUGzMlk6PzdizszN	MlvMV2FPT0WU
NCI-H1650	M13SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPtOGxKSzVyPUG2MlM4PjVizszN	NUHr[lRrW0GQR1XS
Mo-T	NHLrN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj6TndKSzVyPUG3MlQxOjlizszN	Mom1V2FPT0WU
NB7	M3m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4[0WWlEPTB;MUeuO\|Q3PyEQvF2=	NYXaUFF7W0GQR1XS
ES7	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;TSmlEPTB;MUmuOVUxPyEQvF2=	MX3TRW5ITVJ?
ES5	M2rXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\wTWM2OD1{MT63OlcyKM7:TR?=	M3XJR3NCVkeHUh?=
MSTO-211H	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XGVWlEPTB;MkGuPFg2QCEQvF2=	NEDJ[IZUSU6JRWK=
U-87-MG	NIrYRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jCSGlEPTB;MkWuNVk3PiEQvF2=	MVzTRW5ITVJ?
THP-1	M3jhWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;5TWM2OD1{OT63NlAyKM7:TR?=	NX3wcnlSW0GQR1XS
NB10	M2[2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjLUJM3UUN3ME2zNE4zPjl2IN88US=>	NIDVdnJUSU6JRWK=
NH-12	NET0PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LGZmlEPTB;M{OuNlAyPyEQvF2=	MYfTRW5ITVJ?
COLO-824	M3rOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;3SGVXUUN3ME2zOE4yODB4IN88US=>	Mn;qV2FPT0WU
SKM-1	M1rYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\qcnU5UUN3ME2zO{45PDJ{IN88US=>	NYCxfIFmW0GQR1XS
NCI-H1838	NGDtbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzmTWM2OD1\|OD6zO\|k4KM7:TR?=	M2rBNnNCVkeHUh?=
RL	NXTsXIdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTN7LkK0O\|ch\|ryP	MUHTRW5ITVJ?
COLO-800	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnIXINwUUN3ME20NE4xPzd\|IN88US=>	M2i3cnNCVkeHUh?=
KG-1	M{TkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\DeWlEPTB;NECuPFk2PSEQvF2=	M2fC[XNCVkeHUh?=
TUR	NYXvdWh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTRzLk[zPVkh\|ryP	NH\IO21USU6JRWK=
LNCaP-Clone-FGC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PVb2lEPTB;NEGuPVAyPyEQvF2=	NVHhNW5MW0GQR1XS
NCI-H322M	M4PBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn6wTWM2OD12Mj61PVg1KM7:TR?=	MV;TRW5ITVJ?
LNCaP	M1X5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDkT5A1UUN3ME25NU4{KG6P	NFK5PZUzPTVyNUG3OC=>
C4-2	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRThibl2=	MojqNlU2ODVzN{S=
JURKAT	NU\3TYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1fRelI1KGh?		Mk\iTWM2OD12MU[uOlYhdk1?	MXSyOFUyQTl7NR?=
MOLT-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mk[xNlQhcA>?		MWnJR\|UxRTJ6NUOuOUBvVQ>?	NHfwd3ozPDVzOUm5OS=>
REH	M13IeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGPN[HAzPCCq		NHv6UmdKSzVyPUK4O{43QCCwTR?=	Ml;NNlQ2OTl7OUW=
NALM-6	NF3rdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIL5ZWIzPCCq		MmSyTWM2OD1\|NEOzNEBvVQ>?	M1TKWlI1PTF7OUm1
RS 4;11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3XSflI1KGh?		MnrVTWM2OD13MUmuNFUhdk1?	NELMb2kzPDVzOUm5OS=>
697	MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkLINlQhcA>?		M1\3VWlEPTB;MkGwO{4yKG6P	MXWyOFUyQTl7NR?=
SIL-ALL	M1zvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHT6O5EzPCCq		Mm\wTWM2OD1zOUmuO\|chdk1?	NHXoeXIzPDVzOUm5OS=>
CEM	NGmy[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUSyOEBp		NIfVc4RKSzVyPUWyMlE5KG6P	NVr5OVZ[OjR3MUm5PVU>
P12	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV6yOEBp		NYjxS4l[UUN3ME2zPU4zPyCwTR?=	M2XCcFI1PTF7OUm1
NALM-16	NHLzRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NG\zU5gzPCCq		MXvJR\|UxRTl4LkK4JI5O	NVnIOWF5OjR3MUm5PVU>
JURKAT	MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrQ[WNbPDhiaB?=		NYC2fHJbUUN3ME2xOE45PCCwTR?=	MW[yOFUyQTl7NR?=
MOLT-4	NGjvSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlPJOFghcA>?		NFrKdndKSzVyPUK2MlYhdk1?	MV:yOFUyQTl7NR?=
REH	NXTS[2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml\OOFghcA>?		NYrpXYprUUN3ME20OE44OSCwTR?=	MnLvNlQ2OTl7OUW=
NALM-6	NVnQ[npOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVi0PEBp		MYLJR\|UxRTJ\|LkK2JI5O	M{PNXVI1PTF7OUm1
RS 4;11	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVS0PEBp		NEPvXGxKSzVyPUG2OE4zQCCwTR?=	M1;IVlI1PTF7OUm1
697	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnjwOFghcA>?		NF7E[HdKSzVyPUOwOU4{KG6P	NF;sc20zPDVzOUm5OS=>
SIL-ALL	MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvDOFghcA>?		M1;1Z2lEPTB;N{SuOlIhdk1?	NGXhbZczPDVzOUm5OS=>
CEM	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2DKU\|Q5KGh?		Mo\6TWM2OD1{ND61OUBvVQ>?	M1nzPVI1PTF7OUm1
P12	M2fkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mmm4OFghcA>?		NF3UTJpKSzVyPUG4MlQ3KG6P	NGjCc5czPDVzOUm5OS=>
NALM-16	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3r1NFQ5KGh?		MlnITWM2OD14Mz6yOEBvVQ>?	NH;5R5EzPDVzOUm5OS=>
JURKAT	NGfIOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnH0O\|IhcA>?		M3jhT2lEPTB;Mz62OUBvVQ>?	MoTnNlQ2OTl7OUW=
MOLT-4	NWDzOlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlPQO\|IhcA>?		NHvLS3ZKSzVyPUeuN\|khdk1?	NILPV40zPDVzOUm5OS=>
REH	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWW3NkBp		MYfJR\|UxRTF4LkCxJI5O	NIHEOJgzPDVzOUm5OS=>
NALM-6	NWTNN\|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlTDO\|IhcA>?		NXvtZohXUUN3ME2xMlc5KG6P	M2XOdFI1PTF7OUm1
RS 4;11	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2nlZVczKGh?		NXPsbld[UUN3ME20MlM5KG6P	MknSNlQ2OTl7OUW=
697	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{XoTFczKGh?		Mn[0TWM2OD15ND6yPEBvVQ>?	Mnf1NlQ2OTl7OUW=
SIL-ALL	M3S3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmfBO\|IhcA>?		NX\odFR1UUN3ME23MlIhdk1?	NHHQT4QzPDVzOUm5OS=>
CEM	NEHrc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;vV\|czKGh?		NWDGfnd6UUN3ME21MlQzKG6P	Mn2xNlQ2OTl7OUW=
P12	M4fH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{i3UFczKGh?		NV;3epNNUUN3ME22MlM4KG6P	MmryNlQ2OTl7OUW=
NALM-16	M4L2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVTYZYMyPzJiaB?=		MYfJR\|UxRTd5LkezJI5O	M1rVXlI1PTF7OUm1
Y79	Mn63RZBweHSxc3nzJGF{e2G7	Mn;TNU02OCCwTR?=	M4jmdlEzNzJ2IHi=	Ml\FSG1UVw>?	NHvycZlqdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ>	NFjMZmQzPDN4Nk[2OS=>
WER-Rb-1	MXvBdI9xfG:\|aYOgRZN{[Xl?	NUT4cHdXOS13MDDuUS=>	NXXCNXB3OTJxMkSgbC=>	NHuxcpBFVVOR	NGDIRYNqdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ>	NHrOVlczPDN4Nk[2OS=>
G7	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTNwMzDuUS=>	NVTZdZptOjR{MES3N\|M>
G166	NIO4PZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTVTWM2OD15LkCgcm0>	M1fsV\|I1OjB2N{Oz
CB660	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYP6eVNTUUN3ME22MlQhdk1?	NXS4TFllOjR{MES3N\|M>
CB1117	NXS0NVY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF3Lk[gcm0>	Ml3CNlQzODR5M{O=
KB-3-1	NUDzfI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVOwTox{UUN3ME2xMlQ5KMLzIECuOVMhdk1?	NV2xT5huOjN7NkK0OFU>
KB-8-5-11	NITCfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3SyZWlEPTB;NT6wNUDDuSB{LkCxJI5O	NFnlOVEzOzl4MkS0OS=>
KB-C-1	NGn0[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrBTWM2OD1zNj63OkDDuSB2LkWxJI5O	NFi1O5ozOzl4MkS0OS=>
KB-V-1	M3\uc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3DTnVZUUN3ME2yPFEvOjRiwsGgN\|EvPTdibl2=	M1T6cVI{QTZ{NES1
OVCAR-8	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{H6[WlEPTB;Nz6xPUDDuSB\|Lk[wJI5O	NVTndIlbOjN7NkK0OFU>
NCI-ADR-RES	NIraZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFftVphKSzVyPUGyO\|MvOzBiwsGgNVkyNjJyIH7N	MWCyN\|k3OjR2NR?=
MCF7	M1;P[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTPVHJEUUN3ME21MlEyKMLzIEGuOFchdk1?	M1TJc\|I{QTZ{NES1
MCF7-FLV1000	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG2PYlRUUN3ME2zPVMvOThiwsGgO\|QvQDNibl2=	M3HOSVI{QTZ{NES1
S1	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJ2LkOwJOKyKDRwN{Wgcm0>	NX;RWnpWOjN7NkK0OFU>
S1-M1-80	M{WyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PqfWlEPTB;Mk[xMlA3KMLzIES4MlI2KG6P	MnvwNlM6PjJ2NEW=
CORL-23/P	NWD4Z2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFezS\|lKSzVyPUSuN\|ghyrFiMT6yOUBvVQ>?	NX62NlBIOjN7NkK0OFU>
CORL-23/R	NXfiZ4hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULTeXFbUUN3ME21MlE3KMLzIEGuPFMhdk1?	M1fIVlI{QTZ{NES1
NIH3T3	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PpZmlEPTB;NECuOlAhyrFiND65O{BvVQ>?	NIntZZozOzl4MkS0OS=>
NIH3T3-G185	NWGzTYpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;5NXhKSzVyPUK0NVMvPDBiwsGgOFI{NjZ4IH7N	MUmyN\|k3OjR2NR?=
pcDNA-HEK293	NUfRblh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTKRVdKSzVyPUKuO\|UhyrFiMD62O{BvVQ>?	MnzWNlM6PjJ2NEW=
MDR19-HEK293	M4jtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTh3LkWwJOKyKDF\|Lk[3JI5O	NYXrS4x[OjN7NkK0OFU>
R482-HEK293	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLEOoYyUUN3ME2yOU46PyEEsTC0Mlk2KG6P	NVXrXXRMOjN7NkK0OFU>
MRP1-HEK293	NXjkS49VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXoTWM2OD1{Lkm5JOKyKDFwNEmgcm0>	NFPyW\|YzOzl4MkS0OS=>
SF188	M1rzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnS1NVAuOTByIH7N	MnjRNlQuQTZiaB?=	M37PfGROW09?	MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLTDk[ZBm\GWwdDDtZY5v\XJ?	NFLVWJUzOzh6N{[0OS=>
T98G	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHnOVhlOTBvMUCwJI5O	NULL[msxOjRvOU[gbC=>	NIq0bFFFVVOR	NFLKS49qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDjc45k\W62cnH0bY9vNSCmZYDl[IVvfCCvYX7u[ZI>	M2D6WFI{QDh5NkS1
DU145	M13lVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWTYb4RwTE2VTx?=	MWfJR\|Ux6oj:NkCgcm0>	NYnqW4doOjN6OES0Nlg>
LNCaP	NX\VNYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4nHbWROW09?	NX:4fJNYUUN3MPMIwFc2KG6P	NFLYPGozOzh6NESyPC=>
PC3	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkK1SG1UVw>?	Mo\vTWM2OOLKvEG3OUBvVQ>?	M2H4Z\|I{QDh2NEK4
RT4	M3v5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mom0TWM2OD1{Nz6yNUBvVQ>?	MU[yN\|c6OjZ\|OR?=
5637	NUfMfXdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDJOJNKSzVyPUS1MlQ4KG6P	MXqyN\|c6OjZ\|OR?=
T24	M3\WWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjLTWM2OD15OT6xNkBvVQ>?	M4jVTFI{Pzl{NkO5
MCF7	M3\SXWZ2dmO2aX;uJGF{e2G7	MnTTNVAxKG6P	M1zJblEhcA>?	NUfPT253TE2VTx?=	MXvy[YR2[2W\|IITo[UBqdmS3Y4Tpc44hd2cEoFfy[YIyNMLiU3frNUzDqFC\|Mj\|CpHNmenCrbnGzMEBidmUEoGfpd5Az	MoLFNlM4PzB{NES=
KB-V1	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIqxNJpKSzVyPUOuPVIh\|ryP	MXKyN\|U6OzF7Nh?=
Hec50co	NF;iTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rseGlEPTB;NTDuUS=>	M3rrcVI{OTR4Nki3
MDA-MB-468	M33EfGFxd3C2b4Ppd{BCe3OjeR?=	NF[zcnQyNzVxMUCgcm0>	NX7ZUHZQOjRxNEivO\|IhcA>?	MVTEUXNQ	MV3pcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NF3zcHYzOzF2NEK5OC=>
MCF10A	NVXtW251SXCxcITvd4l{KEG\|c3H5	M17Jd\|EwPS9zMDDuUS=>	M4PoZ\|I1NzR6L{eyJIg>	M3mwdGROW09?	MkPpbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	Mlr3NlMyPDR{OUS=
Huh-7	NE\ySYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvEUXlNOS9zMD:xNFAwOTByMDDuUS=>	MorpOFghcA>?		NF;1[5Fl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJk>	NVXnS\|RQOjJ5NEW1PFc>
Daoy	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETEW40yNjh5NT2yOFAhdk1?	NFHuPXU4OiCq	NW\6WIxmTE2VTx?=	MWPJR\|UxRTVibl2=	M{\JOFIzOzlyMke5
ONS-76	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV[xMlg4PS1{NECgcm0>	NVXnbY9sPzJiaB?=	NU\KZYh3TE2VTx?=	MojSTWM2OD15LkWgcm0>	NV\4cll6OjJ\|OUCyO\|k>
SUM 149	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrXNFcxNTFyMDDuUS=>	NFXEcW84OiCq		M1TJd4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	M1;2dlIzOzB7OUO5
MDA-MB-231	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPONE0yODBibl2=	MmC5O\|IhcA>?		MWLpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NYDQdIF3OjJ\|MEm5N\|k>
HR5	NXOwW4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLrNXo6OC1zMECgcm0>	M2DWXFczKGh?		MX;pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	M2XxNFIzOzB7OUO5
BT-474-M1	M{\2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVmwMVExOCCwTR?=	NWfEWWlLPzJiaB?=		NVmwS2RQcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NUDzUWN3OjJ\|MEm5N\|k>
AU565	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi5XZdLOC1zMECgcm0>	NV7ke5l1PzJiaB?=		M12xNolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	M12z[FIzOzB7OUO5
T47D	NWTUR\|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG3NE0yODBibl2=	MV23NkBp		MXnpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	MVqyNlMxQTl\|OR?=
MCF7	M{LTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXMenNrOC1zMECgcm0>	MVy3NkBp		M2e2XYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MmPNNlI{ODl7M{m=
HCT116p53(+/+)	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HabFExNTFyMECgcm0>	M1KwXlI1NzR6IHi=		MUfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=>	NF\CflAzOjJ4MkG3NS=>
HCT116p53(-/-)	NXnGS5NiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWGyeYVzOTBvMUCwNEBvVQ>?	MmTiNlQwPDhiaB?=		MnL0bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJkh[XRiMkWgcm0>	MmXpNlIzPjJzN{G=
HeLa	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILIPXcyOC1zMECgcm0>	MmXVOFghcA>?	MVfEUXNQ	M{PkbGlEPTB;NUKuPUBvVQ>?	Mn3LNlIxQDB{M{W=
HeLa	NGHRe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO5PFVyOTBvMUCwJI5O	NY\qPXhmPzJiaB?=	NXq3XmNqTE2VTx?=	NYLnSGViUUN3ME21NE42KG6P	NXy2dVlLOjJyOECyN\|U>
GBC	NUniXlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1HIdFczKGh?		MVzJR\|UxRTF2Lke4JI5O	MXiyNVk3PTd\|OR?=
GB-CL-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NI\ENoQ4OiCq		NX\QNZNtUUN3ME21MlIzKG6P	MXeyNVk3PTd\|OR?=
Mz-ChA-2	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLjXoY4OiCq		Ml;uTWM2OD1\|LkOxJI5O	MXeyNVk3PTd\|OR?=
TGBC1-TKB	M3zlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV2xOFQhcA>?		MnziTWM2OD14LkeyJI5O	NFrqbZIzOTl4NUezPS=>
Wittier	NXXSepRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;1bFczKGh?		M3WzbGlEPTB;Mz6yOkBvVQ>?	MlLJNlE6PjV5M{m=
H-1	NIC1VI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkXUO\|IhcA>?		M4fBbmlEPTB;OT61OEBvVQ>?	MUOyNVk3PTd\|OR?=
HuH-28	NHX0PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWDnXXJlPzJiaB?=		MYjJR\|UxRTFzLkG5JI5O	MUSyNVk3PTd\|OR?=
NEC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUjw[GhqPzJiaB?=		NEG0N3lKSzVyPUmuPVghdk1?	MYSyNVk3PTd\|OR?=
REB	M4[3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M17mVFczKGh?		M1PqVGlEPTB;MUOuOVEhdk1?	NV;mfI1DOjF7NkW3N\|k>
CC-LP-1	NUe0XWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUS3NkBp		M37KPGlEPTB;NT64OEBvVQ>?	MVGyNVk3PTd\|OR?=
CC-SW-1	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlPaO\|IhcA>?		M3rENWlEPTB;OT61OUBvVQ>?	Mn\SNlE6PjV5M{m=
EGI-1	NXKzWXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUC3NkBp		M4PtRWlEPTB;MUCuO\|Ihdk1?	NGL0U\|AzOTl4NUezPS=>
Sk-ChA-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHrt[YE4OiCq		MWDJR\|UxRTF5LkKgcm0>	NFTlNGMzOTl4NUezPS=>
TFK-1	NYXFNYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVK3NkBp		NHTteIdKSzVyPUGzMlQ2KG6P	MlHqNlE6PjV5M{m=
786-O	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Hib\|UuQDBibl2=	MWe5OkBp	M2D2WGhEdA>?	M1XKPZN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	NF3SfYozOTZ2MkO3OC=>
A498	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUC1MVgxKG6P	MmrBPVYhcA>?	NX7KWGg4UEOu	NEH4[IJ{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	M3rpUVIyPjR{M{e0
ACHN	Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXG1MVgxKG6P	MnjhPVYhcA>?	NYjvU\|NXUEOu	NXjzc\|BHe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MkC2NlE3PDJ\|N{S=
Caki-1	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXwTo9qPS16MDDuUS=>	M3XvTlk3KGh?	NWflUlNiUEOu	M4j3SJN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	NWDMTXZMOjF4NEKzO\|Q>
SN12C	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXXWpc2NThyIH7N	NVzBdo9DQTZiaB?=	NIf2ToJJS2x?	MVXzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	NUnDR3hvOjF4NEKzO\|Q>
HMC-1.1	M3Tw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rM[\|EuOTByMDDuUS=>	NIjyVmQ4OiCq		Mle4bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	M1PVd\|IyOjR{MUi5
HMC-1.2	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDaNU0yODByIH7N	NV\Bb5JpPzJiaB?=		NYnyOJZ3cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	MmfMNlEzPDJzOEm=
C2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xMVExODBibl2=	MXG3NkBp		MYPpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	MoHxNlEzPDJzOEm=
CHP-212	M1;kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jQcVEuOTJ3IH7N	NVjDXpQ5OjRvMUKwJIg>		NHHFOpVqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MojXNlEyPjl{NEK=
IMR-32	NWH0cm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLBNU0yOjVibl2=	NWHZ[5NnOjRvMUKwJIg>		NIrsW2ZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NIDTRZkzOTF4OUK0Ni=>
Kelly	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn0NVBCOS1zMkWgcm0>	NGrBUJozPC1zMkCgbC=>		MlHzbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	Ml7kNlEyPjl{NEK=
SH-EP	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXSxMVEzPSCwTR?=	NXH0UXpuOjRvMUKwJIg>		NI[xdWpqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NYP0XJhLOjFzNkmyOFI>
SH-SY5Y	NIrnR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxMVEzPSCwTR?=	MkXNNlQuOTJyIHi=		MYjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NHTEfI4zOTF4OUK0Ni=>
SK-N-AS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nLXVEuOTJ3IH7N	MXyyOE0yOjBiaB?=		Mlr2bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	Ml\zNlEyPjl{NEK=
SK-N-BE	NY\QcYNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGi5eYQyNTF{NTDuUS=>	M2PXNVI1NTF{MDDo		NFzn[m5qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NWT3cnpUOjFzNkmyOFI>
KG1	NVnhRWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnToNU8yOC9zMECgcm0>	Mli5O\|IhcA>?	MVTEUXNQ	NHX0XWhqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	Mn70NVk1PTh\|NUi=
U937	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fmPFEwOTBxMUCwJI5O	MkTwO\|IhcA>?	MmDtSG1UVw>?	M3zDZolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NYHRV3d3OTl2NUizOVg>
CAL62	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXtRYYxNjFvMUCwJI5O	NX:xdoY4PzJiaB?=	MkPTSG1UVw>?	NYqwU3hWTUN3ME2xMlQhdk1?	NX3TUFg2OTl{MkO1OVM>
OCUT-1	NYLEb2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PqOVAvOS1zMECgcm0>	M2\aXFczKGh?	NFeydlNFVVOR	NVnl[4FXTUN3ME2yMlMhdk1?	M3LkXlE6OjJ\|NUWz
8505C	NH;WN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLpNE4yNTFyMDDuUS=>	NX\EcnBrPzJiaB?=	NFfFVVNFVVOR	M4DicWVEPTB;Mz6yJI5O	M1PBZlE6OjJ\|NUWz
ACT-1	NYTld4twT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\1NE4yNTFyMDDuUS=>	NF;BfWg4OiCq	MlXWSG1UVw>?	MYrFR\|UxRTVwNDDuUS=>	NH3zSYUyQTJ{M{W1Ny=>
SW1736	NICxdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrWTJI3OC5zLUGwNEBvVQ>?	MWq3NkBp	MkW3SG1UVw>?	MWXFR\|UxRTVwNjDuUS=>	MoDrNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

体内研究

BI 2536静脉注射给药多种移植瘤模型，每周一次或两次，效果都很好，通过使细胞周期停滞而抑制细胞增殖，随后诱导肿瘤细胞死亡。BI 2536按 50 mg/kg剂量处理HCT 116移植瘤，每周一次或两次，显著抑制肿瘤生长，T/C 分别为15%和0.3%。BI 2536每周处理两次BxPC-3和A549模型，也显著抑制肿瘤生长，T/C分别为5% 和14%。^[1]

激酶实验： ^[1]	- 合并体外Plk1激酶实验: 重组人Plk1 (1-603残基) 作为氮端，携带杆状病毒表达系统的GST-标记的融合蛋白通过亲和层析，使用谷胱甘肽-琼脂糖而纯化。在梯度稀释的BI 2536存在时，使用 20 ng 重组激酶，及10 μg牛奶中的酪蛋白作为底物进行Plk1 酶活性实验。在终体积为60 μL 的混合物(15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP)中30^oC下进行激酶反应45分钟。加入 125 μL 冰冻的5% TCA终止反应。沉淀物转移到混合酯纤维素的多屏过滤板上，使用1% TCA冲洗实验板，然后利用放射性进行测量。绘制剂量反应曲线，而计算IC50值。
细胞实验：^[1]	- 合并 Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji, PC-3,等等 Concentrations: 溶于DMSO, 终浓度为~1 μM Incubation Time: 24,和72小时 Method: 使用不同浓度BI 2536处理细胞24和72小时。在荧光分光光度计中测量Alamar Blue染料转换而测定细胞生长。为了测定培养基中DNA含量，细胞悬液在80%乙醇中混合, 使用溶于PBS的0.25% Triton X-100处理5分钟，然后与0.1% RNase 和溶于PBS的 10 μg/mL碘化丙啶在室温下温育20分钟。通过流式细胞仪分析而测定细胞周期谱。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 皮下注射HCT 116, NCI-H460, 或A549 细胞的雌性BomTac:NMRI-Foxn1nu 小鼠 Formulation: 在盐酸(0.1 N)中配制，然后在0.9% NaCl中稀释。 Dosages: ~50 mg/kg Administration: 静脉注射，每周一到两次 (Only for Reference)

参考文献

溶解度 (25°C)

体外	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG 400+0.5% Tween 80+5% Propylene glycol	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download BI 2536 SDF

分子量	521.66
化学式	C₂₈H₃₉N₇O₃
CAS号	755038-02-9
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
回答：
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

选择性强的Plk抑制剂

GSK461364 : Plk1-selective, K_i=2.2 nM.
用于临床的Plk抑制剂

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
最新的Plk抑制剂

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
经典的Plk抑制剂

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

研究领域

产品类型

BI 2536

客户使用Selleck生产的BI 2536发表文献134篇：

产品安全说明书

PLK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download BI 2536 SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

相关PLK产品